Calcium Channel Blockers: Inhibitors of Tumor Cell-Platelet-Endothelial Cell Interactions

  • James M. Onoda
  • Bonnie F. Sloane
  • John D. Taylor
  • Kenneth V. Honn
Part of the Developments in Oncology book series (DION, volume 22)


The movement of calcium ions across cellular membranes (e. g., plasma membrane, endoplasmic or sarcoplasmic reticulum) can serve as a molecular messenger that modulates biochemical processes appropriate to the specific cell type. Calcium antagonists by preventing release of Ca2+ from intracellular stores, by peventing influx of external Ca2+ or by inhibiting the effects of Ca2+ through interactions with Ca2+-binding proteins such as calmodulin can interfere with these biochemical functions. The primary action of one subgroup of calcium antagonists is to interact with the channels in the cell membrane through which calcium enters the cells. This class of compounds originally described by Fleckenstein has been called by a variety of names including Ca2+-channel blockers, Ca2+-entry blockers, Ca2+-channel inhibitors and slow-channel blockers (for review see 1–3). We will use the terminology calcium channel blockers (CCB) in this chapter.


Platelet Aggregation Calcium Channel Blocker Platelet Rich Plasma Inhibit Platelet Aggregation Synergistic Inhibition 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fleckenstein A. Annu. Rev. Pharmacol. Toxicol. 17: 149–166, 1977.CrossRefGoogle Scholar
  2. 2.
    Janis RA and Triggle RJ. J. Med. Chem. 26: 775–785, 1983.PubMedCrossRefGoogle Scholar
  3. 3.
    Braunwald E. N. Engl. J. Med. 307: 1618–1627, 1982.CrossRefGoogle Scholar
  4. 4.
    Murphy KMM, Gould RJ, Largent BL and Snyder SH. Proc. Natl. Acad. Sci. USA 80: 860–864, 1983.CrossRefGoogle Scholar
  5. 5.
    Nayler WS and Grinwald P. Fed. Proc. Fed. Am. Soc. Exp. Biol. 40: 2855–2861, 1981.Google Scholar
  6. 6.
    Lee KS and Tsien RW. Nature (London) 302: 790–794, 1983.CrossRefGoogle Scholar
  7. 7.
    Janis RA and Scriabine A. Biochem. Pharmacol. 32: 3499–3507, 1983.PubMedCrossRefGoogle Scholar
  8. 8.
    Wellens D, Goossens T and Reyntjens A. Angiology 12: 821–827, 1980.CrossRefGoogle Scholar
  9. 9.
    Conti CR. J. Fl. Med. Assoc. 68: 883–886, 1981.Google Scholar
  10. 10.
    Murphy KMM and Synder SH. Eur. J. Pharmacol. 77: 201–202, 1982.PubMedCrossRefGoogle Scholar
  11. 11.
    Motulsky HJ, Snavely MD, Hughes RJ and Insel PA. Circ. Res. 52: 226–231, 1983.PubMedGoogle Scholar
  12. 12.
    Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y. Cancer Res. 43: 2267–2272, 1983.PubMedGoogle Scholar
  13. 13.
    Tsuruo T, Iida H, Nojiri M, Tsukagoshi S and Sakurai Y. Cancer Res. 43: 2905–2910, 1983.PubMedGoogle Scholar
  14. 14.
    Kaelin WG, Shrivastav S, Shand DG and Jirtle RL. Cancer Res. 42: 3944–3949, 1982.PubMedGoogle Scholar
  15. 15.
    Winquist RJ, Webb RC and Bohr DF. Fed. Proc. Fed. Am. Soc. Exp. Biol. 40: 2852–2854, 1981.Google Scholar
  16. 16.
    Honn KV, Menter DG, Onoda JM, Taylor JD and Sloane BF. In: Cancer Invasion and Metastasis (Eds. Nicolson GL and Milas L), Raven Press: New York, pp. 361–388, 1984.Google Scholar
  17. 17.
    Bastida E, Ordinas A and Jamieson GA. Nature (London) 291: 661–662, 1981.CrossRefGoogle Scholar
  18. 18.
    Hara Y, Steiner M and Baldini MS. Cancer Res. 40: 1217–1222, 1980.PubMedGoogle Scholar
  19. 19.
    Karpatkin S, Smerling A and Pearlstein E. J. Lab. Clin. Med. 96: 994–1001, 1980.Google Scholar
  20. 20.
    Gasic GJ, Gasic TB and Stewart CC. Proc. Natl. Acad. Sci. USA 61: 46–52, 1968.PubMedCrossRefGoogle Scholar
  21. 21.
    Gastpar H, Ambrus J and Thurber LE. J. Med. 8: 53–56, 1977.PubMedGoogle Scholar
  22. 22.
    Gasic GJ, Gasic TB, Galanti N, Johnson T and Murphy J. Int. J. Cancer 11: 704–718, 1973.PubMedCrossRefGoogle Scholar
  23. 23.
    Honn KV, Busse WD and Sloane BF. Biochem. Pharmacol. 32: 1–11, 1983.PubMedCrossRefGoogle Scholar
  24. 24.
    Menter DG, Onoda JM, Taylor JD and Honn KV. Cancer Res. 44: 450–456, 1984.PubMedGoogle Scholar
  25. 25.
    Lerner WA, Pearlstein E, Ambrogio C and Karpatkin S. Int. J. Cancer 31: 463–469, 1983.PubMedCrossRefGoogle Scholar
  26. 26.
    Honn KV. Clin. Exp. Metastasis 1: 103–114, 1983.CrossRefGoogle Scholar
  27. 27.
    Honn KV, Cicone B and Skoff A. Science 212: 1270–1272, 1981.PubMedCrossRefGoogle Scholar
  28. 28.
    Owen NE, Feinberg H and Lebreton GC. Am. J. Physiol. 239: H483–H488, 1980.PubMedGoogle Scholar
  29. 29.
    Owen NE and Lebreton GC. Am. J. Physiol. 241: H613–H619, 1981.PubMedGoogle Scholar
  30. 30.
    Miller OV, Johnson RA and Gorman RR. Prostaglandins 13: 599–609, 1977.PubMedCrossRefGoogle Scholar
  31. 31.
    Gorman RR. Fed. Proc. Fed. Am. Soc. Exp. Biol. 38: 83–88, 1979.Google Scholar
  32. 32.
    Fleckenstein A. Arzneim.Forsch./Drug Res. 20: 1317–1322, 1970.Google Scholar
  33. 33.
    Godfraind T. Fed. Proc. Fed. Am. Soc. Exp. Biol. 40: 2866–2871, 1981.Google Scholar
  34. 34.
    Ono H and Kimura M. Arzneim.Forsch./Drug Res. 31: 1131–1134, 1981.Google Scholar
  35. 35.
    Schmunk GA and Lefer AM. Res. Commun. Chem. Pathol. Pharmacol. 35: 179–187, 1982.PubMedGoogle Scholar
  36. 36.
    Ribeiro LGT, Brandon TA, Horak JK, Ware JA, Miller RR and Solis RT. J. Cardiovas. Pharmacol. 4: 170–173, 1982.CrossRefGoogle Scholar
  37. 37.
    Han P, Boatwright C and Ardlie NG. Thromb. Haemostas. 50: 513–517, 1983.Google Scholar
  38. 38.
    Dale J, Landmark KH and Myhre E. Am. Heart J. 105: 103–105, 1983.PubMedCrossRefGoogle Scholar
  39. 39.
    Shinjo A, Sasaki Y, Inamasu M and Morita T. Thromb. Res. 13: 941–955, 1978.PubMedCrossRefGoogle Scholar
  40. 40.
    Okamatsu S, Peck RC and Lefer AM. Proc. Soc. Exp. Biol. Med. 166: 551–555, 1981.PubMedGoogle Scholar
  41. 41.
    Ikeda Y, Kikuchi M, Toyama K, Wantanabe K and Ando Y. Thromb. Haemostasis 45: 158–161, 1981.Google Scholar
  42. 42.
    Addonizio VP, Fisher CA, Strauss JF and Edmunds LH. Thromb. Res. 28: 545–556, 1982.PubMedCrossRefGoogle Scholar
  43. 43.
    Mehta J, Mehta P, Ostrowski N and Crews F. Thromb. Res. 30: 469–475, 1983.PubMedCrossRefGoogle Scholar
  44. 44.
    Maclntyre DE and Shaw AM. Thromb. Res. 21: 833–844, 1983.CrossRefGoogle Scholar
  45. 45.
    Mehta P, tfehta J, Ostrowski N and Brigmon L. J. Lab. Clin. Med. 102: 332–339, 1983.Google Scholar
  46. 46.
    Schomerus M, Spiegelhalder B, Stevens B and Eichelbaum K. Cardiovas. Res. 10: 605–612, 1976.CrossRefGoogle Scholar
  47. 47.
    Foster TS, Hamann SR, Richards VR, Bryant PJ, Graves DA and McAllister RG. J. Clin. Pharmacol. 23: 161–170, 1983.Google Scholar
  48. 48.
    Rybicki JP and LeBreton GC. Thromb. Res. 30: 407–414, 1983.PubMedCrossRefGoogle Scholar
  49. 49.
    Onoda JM, Sloane BF and Honn KV. Submitted.Google Scholar
  50. 50.
    Honn KV, Onoda JM, Diglio CA, Carufel MM, Taylor JD and Sloane BF. Clin. Exp. Metastasis, in press.Google Scholar
  51. 51.
    Honn KV, Onoda JM, Diglio CA and Sloane BF. Proc. Soc. Exp. Biol. Med. 174: 16–19, 1983.Google Scholar
  52. 52.
    Honn KV, Onoda JM, Pampalona K, Battaglia M, Neagos G, Taylor JD, Diglio CA and Sloane BF. Submitted.Google Scholar
  53. 53.
    Gerold M, Eigenmann R and Haeusler G. J. Cardiovas. Pharmacol. 4: 419–429, 1982.CrossRefGoogle Scholar
  54. 54.
    Norman JA, Ansell J and Phillips MA. Eur. J. Pharmacol. 93: 107–112, 1983.PubMedCrossRefGoogle Scholar
  55. 55.
    Bostrum SL, Ljung B, Mardh S, Forsen S and Thulin E. Nature (London) 292: 777–778, 1981.CrossRefGoogle Scholar
  56. 56.
    Srivastava KC and Awasthi KK. Prostaglandins Leukotrienes Med. 10: 411–417, 1983.CrossRefGoogle Scholar
  57. 57.
    Maniglia CA, Tudor G, Gomez J and Sartorelli AC. Cancer Lett. 16: 253–260, 1982.CrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1984

Authors and Affiliations

  • James M. Onoda
  • Bonnie F. Sloane
  • John D. Taylor
  • Kenneth V. Honn

There are no affiliations available

Personalised recommendations